TICKERNERD
Menu
CBLLCBLLHealthcare · Medical Devices

CBLL Stock Forecast: Ceribell, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$23
−1.41% on the day

The 8 Wall Street analysts covering Ceribell, Inc. hold a median 12-month price target of $29 — +25.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$888.5M
Ticker Nerd rank
38 / 100
Median analyst target
$29
Analysts covering
8
Revenue$28.1M+32.5% y/y
Operating income−$20.0M
Net income−$19.3M
Free cash flow−$12.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
−4.8%
YTD
+5.6%
1Y
+89.1%
From 52W high
−7.5%
From 52W low
+112.0%
$11
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CBLL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ceribell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Accruals
69
Volatility
49
Size
46
Value
45
Revisions
39
Quality
36
Growth
29
Issuance
25

Momentum (91): The shares have been drifting up relative to others.

Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CBLL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CBLL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26CBLLHigh $33Median $29Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $24Median $29High $33

The green dot is the last close — the median target sits +25.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
2 Oct 2026TD CowenMaintainsBuy$29 → $33
11 Sept 2026BTIGReiteratesBuy—
11 Sept 2026BTIGReiteratesBuy$30
18 Aug 2026BTIGMaintainsBuy$28 → $30
18 Aug 2026BTIGMaintainsBuy—
11 Aug 2026BTIGReiteratesBuy—
11 Aug 2026BTIGReiteratesBuy$28
11 Aug 2026Canaccord GenuityMaintainsBuy—
11 Aug 2026Canaccord GenuityMaintainsBuy$25 → $26
12 May 2026Canaccord GenuityMaintainsBuy—
12 May 2026Canaccord GenuityMaintainsBuy$28 → $25
28 Jan 2026BTIGReiteratesBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
15 Dec 2025BTIGReiteratesBuy—
5 Nov 2025JP MorganMaintainsOverweight—
5 Nov 2025TD CowenMaintainsBuy—
21 Oct 2025Raymond JamesInitiatesStrong Buy—
4 Apr 2025Ladenburg ThalmannInitiatesBuy—
26 Feb 2025Canaccord GenuityMaintainsBuy—
9 Dec 2024Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CBLL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CBLL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Ceribell, Inc. returned +89.1% against +16.2% for the S&P 500, dividends included.

CBLL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26CBLLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CBLL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Ceribell, Inc. (CBLL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.9×

Cheaper than 95% of US stocks

Price / sales
8.7×

Cheaper than 16% of US stocks

Price / book
6.9×

Cheaper than 14% of US stocks

EV / EBITDA
−11.5×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
32.5%

Higher than 79% of US stocks

Earnings growth (YoY)
32.5%

Higher than 67% of US stocks

Gross margin
92.3%

Higher than 97% of US stocks

Operating margin
−71.1%

Higher than 15% of US stocks

Net margin
−64.7%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−43.9%

Higher than 23% of US stocks

Return on assets
−23.4%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ceribell, Inc. (CBLL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ceribell, Inc. has a market value of $888.5M and an enterprise value of $793.8M.

  • Revenue in the twelve months to 30 June 2026: $102.0M. The latest quarter grew 32.5% year on year.

  • Net income over the same four quarters: −$66.0M, a −64.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.76.

  • Free cash flow in the twelve months to 30 June 2026: −$54.7M.

  • Shares outstanding: 38.2M.

  • Trailing P/E: −15.9×; forward P/E: −14.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ceribell, Inc. employs 327 people — $312K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

CBLL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CBLLCeribell, Inc.$888.5M
38
QDELQuidelOrtho Corp.$846.3M
33
SIBNSI-BONE, Inc.$833.0M
73
AHCOAdaptHealth Corp.$824.3M
44
INMDInMode Ltd.$809.3M
75
BBNXBeta Bionics, Inc.$917.5M
37
VREXVarex Imaging Corp.$774.3M
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ceribell, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CBLL news & analysis

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

GlobeNewsWire · 30 Sept 2026positive

Ceribell announced that the U.S. FDA cleared new software for the Ceribell System featuring quantitative EEG trending and amplitude-integrated EEG analysis. The company said the software makes it faster and easier for clinicians to interpret longitudinal brain activity and make clinical decisions.

Why it matters — A new FDA clearance for Ceribell's EEG analysis software strengthens the company's product offering and could help clinicians more quickly interpret brain-monitoring data.

CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push

MarketBeat · 12 Aug 2026positive

CeriBell outlined plans to expand its brainwave-monitoring platform beyond seizure detection, introducing new products for delirium and pediatric patients, with stroke as a future target, while continuing to build its hospital customer base.

Why it matters — A CBLL watcher would care because the company's expansion into additional clinical indications signals a broader product pipeline and continued growth in its hospital customer base.

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

CeriBell, Inc. held its Q2 2026 earnings call, and the full conference call transcript has been published on Seeking Alpha. The transcript covers the company's quarterly earnings discussion for the period.

Why it matters — A CBLL watcher would care because the earnings call transcript provides insight into the company's quarterly financial results and management commentary.

Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings

Zacks Investment Research · 11 Aug 2026neutral

Zacks coverage of CeriBell, Inc.'s Q2 (ending June 2026) earnings highlights that while revenue and EPS reflect business performance, key metrics should also be compared against Wall Street estimates and year-ago figures. The item focuses on evaluating these metrics for the quarter.

Why it matters — A CBLL watcher would care because this analysis offers a more detailed view of how the company's core metrics stack up against analyst expectations and prior-year performance beyond just the headline revenue and EPS.

CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 10 Aug 2026negative

Ceribell, Inc. reported a Q2 loss of $0.51 per share, wider than both the Zacks Consensus Estimate of a $0.45 loss and the $0.38 loss from the same quarter a year ago, though revenue exceeded expectations.

Why it matters — For CBLL watchers, the quarterly results show a larger-than-expected loss despite topping revenue estimates, highlighting ongoing bottom-line pressure.

FAQ

Frequently asked questions about CBLL stock

What is the CBLL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Ceribell, Inc. have a median 12-month price target of $29, with estimates ranging from $24 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CBLL stock a buy right now?

Of the 8 analysts covering Ceribell, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ceribell, Inc. 38 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CBLL?

As at 8 Oct 2026, Ceribell, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will CBLL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +25.3% from the last close, and Ticker Nerd's factor model ranks Ceribell, Inc. 38 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CBLL stock forecast for 2030?

No analyst covering Ceribell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CBLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $33 over the next 12 months.

How has CBLL stock performed over the past year?

Ceribell, Inc. returned +89.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ceribell, Inc. do?

Ceribell Inc. is a medical technology company focused on acute-care neurodiagnostics.

What is the latest news on CBLL?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis". Ceribell announced that the U.S. FDA cleared new software for the Ceribell System featuring quantitative EEG trending and amplitude-integrated EEG analysis. The company said the software makes it faster and easier for clinicians to interpret longitudinal brain activity and make clinical decisions.

Company

About Ceribell, Inc.

Ceribell Inc. is a medical technology company focused on acute-care neurodiagnostics. Ceribell develops the Ceribell System, a point-of-care EEG platform designed to help clinicians detect and manage serious neurological conditions at the bedside. Its product suite includes disposable EEG headbands, a portable battery-operated recorder, cloud-based EEG software, and Clarity, an AI-powered seizure detection algorithm. These tools are used in hospitals and other urgent-care settings to support rapid brain monitoring, real-time interpretation, and faster clinical decision-making. Ceribell’s technology is aimed at making EEG more accessible, efficient, and practical for frontline healthcare teams working with suspected seizures and other critical neurological events.

CEO Dr. Xingjuan Chao Ph.D. · 327 employees · United States · https://www.ceribell.com